US9314005B2
(en)
|
2009-07-01 |
2016-04-19 |
Transposagen Biopharmaceuticals, Inc. |
Genetically modified rat models for severe combined immunodeficiency (SCID)
|
JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
GB201117313D0
(en)
|
2011-10-07 |
2011-11-16 |
Gt Biolog Ltd |
Bacterium for use in medicine
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
WO2013139861A1
(en)
|
2012-03-20 |
2013-09-26 |
Luc Montagnier |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
CN104364380B
(zh)
|
2012-04-25 |
2018-10-09 |
瑞泽恩制药公司 |
核酸酶介导的使用大靶向载体的靶向
|
ES2636902T3
(es)
|
2012-05-25 |
2017-10-10 |
The Regents Of The University Of California |
Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
|
HUE030799T2
(en)
|
2012-07-11 |
2017-06-28 |
Sangamo Biosciences Inc |
Methods and preparations for the treatment of lysosomal storage diseases
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
AU2013293270B2
(en)
*
|
2012-07-25 |
2018-08-16 |
Massachusetts Institute Of Technology |
Inducible DNA binding proteins and genome perturbation tools and applications thereof
|
SG10201809566SA
(en)
|
2012-10-23 |
2018-11-29 |
Toolgen Inc |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
CN105142669B
(zh)
|
2012-12-06 |
2018-07-03 |
西格马-奥尔德里奇有限责任公司 |
基于crispr的基因组修饰和调控
|
EP3144390B1
(en)
|
2012-12-12 |
2020-03-18 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions for sequence manipulation
|
CN105658796B
(zh)
|
2012-12-12 |
2021-10-26 |
布罗德研究所有限公司 |
用于序列操纵的crispr-cas组分系统、方法以及组合物
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
EP2931892B1
(en)
|
2012-12-12 |
2018-09-12 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
ES2576126T3
(es)
*
|
2012-12-12 |
2016-07-05 |
The Broad Institute, Inc. |
Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
AU2013359199C1
(en)
|
2012-12-12 |
2021-06-17 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
EP4282970A3
(en)
|
2012-12-17 |
2024-01-17 |
President and Fellows of Harvard College |
Rna-guided human genome engineering
|
EP3919505B1
(en)
|
2013-01-16 |
2023-08-30 |
Emory University |
Uses of cas9-nucleic acid complexes
|
WO2014130706A1
(en)
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
EP3620534B1
(en)
|
2013-03-14 |
2021-10-13 |
Caribou Biosciences, Inc. |
Crispr-cas compositions of nucleic acid-targeting nucleic acids
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
CA2907198C
(en)
|
2013-03-15 |
2019-12-10 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
CN115261411A
(zh)
|
2013-04-04 |
2022-11-01 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
GB201306536D0
(en)
|
2013-04-10 |
2013-05-22 |
Gt Biolog Ltd |
Polypeptide and immune modulation
|
WO2014172470A2
(en)
*
|
2013-04-16 |
2014-10-23 |
Whitehead Institute For Biomedical Research |
Methods of mutating, modifying or modulating nucleic acid in a cell or nonhuman mammal
|
DK2986729T3
(en)
|
2013-04-16 |
2018-10-29 |
Regeneron Pharma |
TARGETED MODIFICATION OF ROOT THROUGH
|
WO2014186686A2
(en)
*
|
2013-05-17 |
2014-11-20 |
Two Blades Foundation |
Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
|
US11685935B2
(en)
*
|
2013-05-29 |
2023-06-27 |
Cellectis |
Compact scaffold of Cas9 in the type II CRISPR system
|
US20150067922A1
(en)
*
|
2013-05-30 |
2015-03-05 |
The Penn State Research Foundation |
Gene targeting and genetic modification of plants via rna-guided genome editing
|
CA2915837A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
SG11201510286QA
(en)
|
2013-06-17 |
2016-01-28 |
Broad Inst Inc |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
|
AU2014281026B2
(en)
|
2013-06-17 |
2020-05-28 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
DK3011031T3
(da)
|
2013-06-17 |
2020-12-21 |
Broad Inst Inc |
Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
US10011850B2
(en)
|
2013-06-21 |
2018-07-03 |
The General Hospital Corporation |
Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
|
JP2016528890A
(ja)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いるゲノム編集の治療用の使用
|
CA2917639C
(en)
*
|
2013-07-10 |
2024-01-02 |
President And Fellows Of Harvard College |
Orthogonal cas9 proteins for rna-guided gene regulation and editing
|
US10563225B2
(en)
|
2013-07-26 |
2020-02-18 |
President And Fellows Of Harvard College |
Genome engineering
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
MX363842B
(es)
|
2013-08-22 |
2019-04-05 |
Du Pont |
Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
|
EP3038661B1
(en)
|
2013-08-29 |
2023-12-27 |
Temple University Of The Commonwealth System Of Higher Education |
Methods and compositions for rna-guided treatment of hiv infection
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
DE202014010413U1
(de)
|
2013-09-18 |
2015-12-08 |
Kymab Limited |
Zellen und Organismen
|
WO2015054507A1
(en)
|
2013-10-10 |
2015-04-16 |
Pronutria, Inc. |
Nutritive polypeptide production systems, and methods of manufacture and use thereof
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
LT3066201T
(lt)
|
2013-11-07 |
2018-08-10 |
Editas Medicine, Inc. |
Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
|
US20160298096A1
(en)
*
|
2013-11-18 |
2016-10-13 |
Crispr Therapeutics Ag |
Crispr-cas system materials and methods
|
US9074199B1
(en)
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
RU2725520C2
(ru)
|
2013-12-11 |
2020-07-02 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
WO2015089473A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
AU2014362248A1
(en)
|
2013-12-12 |
2016-06-16 |
Massachusetts Institute Of Technology |
Compositions and methods of use of CRISPR-Cas systems in nucleotide repeat disorders
|
KR20160089527A
(ko)
*
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
게놈 편집을 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료적 응용
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
EP3080260B1
(en)
|
2013-12-12 |
2019-03-06 |
The Broad Institute, Inc. |
Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
CN111269902A
(zh)
|
2013-12-12 |
2020-06-12 |
布罗德研究所有限公司 |
Crispr-cas系统和组合物的递送及用途
|
CA2932475A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute, Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
DK3105328T3
(da)
|
2014-02-11 |
2020-07-13 |
Univ Colorado Regents |
Multiplexet genom manipulation ved hjælp af CRISPR
|
MX2016010781A
(es)
|
2014-02-18 |
2017-02-15 |
Univ Duke |
Composiciones para la inactivacion de la replicacion de virus y metodos de fabricacion y uso de las mismas.
|
CN106232803A
(zh)
|
2014-02-27 |
2016-12-14 |
孟山都技术公司 |
用于定点基因组修饰的组合物和方法
|
EP3514246B1
(en)
|
2014-02-27 |
2021-11-17 |
The Broad Institute, Inc. |
T cell balance gene expression and methods of use thereof
|
EP3957735A1
(en)
|
2014-03-05 |
2022-02-23 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
WO2015138510A1
(en)
|
2014-03-10 |
2015-09-17 |
Editas Medicine., Inc. |
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
EP3981876A1
(en)
|
2014-03-26 |
2022-04-13 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating sickle cell disease
|
EP4123024A1
(en)
*
|
2014-04-01 |
2023-01-25 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
|
WO2015157252A1
(en)
|
2014-04-07 |
2015-10-15 |
BROGDON, Jennifer |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
EP3129485B2
(en)
|
2014-04-09 |
2022-12-21 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating cystic fibrosis
|
AU2015266776A1
(en)
|
2014-05-30 |
2016-12-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
CN106795521B
(zh)
|
2014-06-06 |
2021-06-04 |
瑞泽恩制药公司 |
用于修饰所靶向基因座的方法和组合物
|
EP3154694A1
(en)
|
2014-06-13 |
2017-04-19 |
Children's Medical Center Corporation |
Products and methods to isolate mitochondria
|
KR102425438B1
(ko)
|
2014-06-23 |
2022-07-27 |
더 제너럴 하스피탈 코포레이션 |
서열결정에 의해 평가된 DSB의 게놈 전체에 걸친 비편향된 확인 (GUIDE-Seq)
|
KR102468108B1
(ko)
|
2014-06-26 |
2022-11-18 |
리제너론 파마슈티칼스 인코포레이티드 |
표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
|
WO2016007347A1
(en)
|
2014-07-11 |
2016-01-14 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
CN104152414B
(zh)
*
|
2014-07-18 |
2018-03-13 |
中国科学院广州生物医药与健康研究院 |
对细胞基因组的预定位点进行基因改造的方法
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
AU2015292755B2
(en)
|
2014-07-21 |
2020-11-12 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
EP3177718B1
(en)
*
|
2014-07-30 |
2022-03-16 |
President and Fellows of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
KR101817482B1
(ko)
*
|
2014-08-06 |
2018-02-22 |
주식회사 툴젠 |
캄필로박터 제주니 crispr/cas 시스템 유래 rgen을 이용한 유전체 교정
|
JP6837429B2
(ja)
*
|
2014-08-11 |
2021-03-03 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
Crispr/cas9媒介遺伝子編集による筋ジストロフィーの予防
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
DK3180426T3
(da)
*
|
2014-08-17 |
2020-03-30 |
Broad Inst Inc |
Genomredigering ved anvendelse af cas9-nickaser
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
DK3186376T3
(da)
|
2014-08-27 |
2019-05-06 |
Caribou Biosciences Inc |
Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
CA2956487A1
(en)
|
2014-09-12 |
2016-03-17 |
E. I. Du Pont De Nemours And Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
MX2017003645A
(es)
|
2014-09-17 |
2017-05-30 |
Novartis Ag |
Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
US10040048B1
(en)
|
2014-09-25 |
2018-08-07 |
Synthego Corporation |
Automated modular system and method for production of biopolymers
|
CN104546931B
(zh)
*
|
2014-09-30 |
2019-04-09 |
深圳华大基因科技有限公司 |
华德萨特氏菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
|
US20160090603A1
(en)
*
|
2014-09-30 |
2016-03-31 |
Sandia Corporation |
Delivery platforms for the domestication of algae and plants
|
US10583201B2
(en)
*
|
2014-10-10 |
2020-03-10 |
Massachusetts Eye And Ear Infirmary |
Efficient delivery of therapeutic molecules in vitro and in vivo
|
US20170247762A1
(en)
|
2014-10-27 |
2017-08-31 |
The Board Institute Inc. |
Compositions, methods and use of synthetic lethal screening
|
AU2015342749B2
(en)
|
2014-11-07 |
2022-01-27 |
Editas Medicine, Inc. |
Methods for improving CRISPR/Cas-mediated genome-editing
|
WO2016080795A1
(ko)
*
|
2014-11-19 |
2016-05-26 |
기초과학연구원 |
두 개의 벡터로부터 발현된 cas9 단백질을 이용한 유전자 발현 조절 방법
|
US10362771B2
(en)
|
2014-11-20 |
2019-07-30 |
Kyoto University |
Method for knock-in of DNA into target region of mammalian genome, and cell
|
NZ731962A
(en)
|
2014-11-21 |
2022-07-01 |
Regeneron Pharma |
Methods and compositions for targeted genetic modification using paired guide rnas
|
EP3224381B1
(en)
|
2014-11-25 |
2019-09-04 |
The Brigham and Women's Hospital, Inc. |
Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease
|
EP3224362A4
(en)
|
2014-11-26 |
2018-06-06 |
The Regents of The University of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
JP7068821B2
(ja)
|
2014-12-03 |
2022-05-17 |
アジレント・テクノロジーズ・インク |
化学修飾を有するガイドrna
|
AU2015360502A1
(en)
|
2014-12-10 |
2017-06-29 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
WO2016094880A1
(en)
*
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
EP3985115A1
(en)
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
DK3234133T3
(da)
*
|
2014-12-18 |
2021-02-08 |
Integrated Dna Tech Inc |
Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
|
CN107208113A
(zh)
|
2014-12-19 |
2017-09-26 |
瑞泽恩制药公司 |
用于通过单步多重靶向进行靶向遗传修饰的方法和组合物
|
WO2016098078A2
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Dimerization switches and uses thereof
|
WO2016100974A1
(en)
|
2014-12-19 |
2016-06-23 |
The Broad Institute Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
CN113337533A
(zh)
|
2014-12-23 |
2021-09-03 |
先正达参股股份有限公司 |
用于鉴定和富集包含位点特异性基因组修饰的细胞的方法和组合物
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
KR102523805B1
(ko)
|
2014-12-23 |
2023-04-20 |
4디 파마 리서치 리미티드 |
면역 조정
|
AU2015370665B2
(en)
|
2014-12-23 |
2020-05-14 |
4D Pharma Research Limited |
Pirin polypeptide and immune modulation
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
US11208638B2
(en)
|
2015-01-12 |
2021-12-28 |
The Regents Of The University Of California |
Heterodimeric Cas9 and methods of use thereof
|
EP4257690A3
(en)
|
2015-01-28 |
2024-03-27 |
Caribou Biosciences, Inc. |
Crispr hybrid dna/rna polynucleotides and methods of use
|
WO2016123243A1
(en)
|
2015-01-28 |
2016-08-04 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
EP3262162A4
(en)
*
|
2015-02-23 |
2018-08-08 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
WO2016138488A2
(en)
|
2015-02-26 |
2016-09-01 |
The Broad Institute Inc. |
T cell balance gene expression, compositions of matters and methods of use thereof
|
CN109121418A
(zh)
|
2015-03-02 |
2019-01-01 |
西奈健康系统 |
同源重组因子
|
EP3858990A1
(en)
|
2015-03-03 |
2021-08-04 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
CN107567499A
(zh)
|
2015-03-27 |
2018-01-09 |
纳幕尔杜邦公司 |
大豆u6核小rna基因启动子及其在植物小rna基因的组成型表达中的用途
|
EP3277816B1
(en)
*
|
2015-04-01 |
2020-06-17 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
|
EP3280803B1
(en)
*
|
2015-04-06 |
2021-05-26 |
The Board of Trustees of the Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
US11180793B2
(en)
|
2015-04-24 |
2021-11-23 |
Editas Medicine, Inc. |
Evaluation of Cas9 molecule/guide RNA molecule complexes
|
WO2016182893A1
(en)
|
2015-05-08 |
2016-11-17 |
Teh Broad Institute Inc. |
Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
US11390884B2
(en)
|
2015-05-11 |
2022-07-19 |
Editas Medicine, Inc. |
Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
|
WO2016183438A1
(en)
*
|
2015-05-14 |
2016-11-17 |
Massachusetts Institute Of Technology |
Self-targeting genome editing system
|
US11371050B2
(en)
*
|
2015-05-15 |
2022-06-28 |
Pioneer Hi-Bred International, Inc. |
Rapid characterization of Cas endonuclease systems, PAM sequences and guide RNA elements
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
CA3000182A1
(en)
*
|
2015-05-29 |
2016-12-08 |
Agenovir Corporation |
Methods and compositions for treating cells for transplant
|
WO2016196887A1
(en)
|
2015-06-03 |
2016-12-08 |
Board Of Regents Of The University Of Nebraska |
Dna editing using single-stranded dna
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
EP3307887A1
(en)
|
2015-06-09 |
2018-04-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
MA41060B1
(fr)
|
2015-06-15 |
2019-11-29 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
SG10201912320TA
(en)
|
2015-06-15 |
2020-02-27 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
HUE045754T2
(hu)
|
2015-06-15 |
2020-01-28 |
4D Pharma Res Ltd |
Blautia stercosis és wexlerae gyulladásos és autoimmun betegségek kezelésében történõ alkalmazásra
|
MA41010B1
(fr)
|
2015-06-15 |
2020-01-31 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
WO2016203221A1
(en)
|
2015-06-15 |
2016-12-22 |
4D Pharma Research Limited |
Compositions comprising bacterial strains
|
EP3310932B1
(en)
|
2015-06-17 |
2023-08-30 |
The UAB Research Foundation |
Crispr/cas9 complex for genomic editing
|
CN108026545A
(zh)
|
2015-06-17 |
2018-05-11 |
Uab研究基金会 |
用于将功能性多肽引入到血细胞谱系细胞中的crispr/cas9复合物
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
EP3430134B1
(en)
|
2015-06-18 |
2022-09-21 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
WO2016205745A2
(en)
*
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
TWI813532B
(zh)
*
|
2015-06-18 |
2023-09-01 |
美商博得學院股份有限公司 |
降低脱靶效應的crispr酶突變
|
WO2016205749A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
CA2990699A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
US10456452B2
(en)
|
2015-07-02 |
2019-10-29 |
Poseida Therapeutics, Inc. |
Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
|
US20170000743A1
(en)
*
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
US20170119820A1
(en)
|
2015-07-31 |
2017-05-04 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
US9580727B1
(en)
|
2015-08-07 |
2017-02-28 |
Caribou Biosciences, Inc. |
Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
JP2018529759A
(ja)
|
2015-08-14 |
2018-10-11 |
ザ ユニバーシティー オブ シドニー |
治療用コネキシン45阻害剤
|
WO2017031370A1
(en)
|
2015-08-18 |
2017-02-23 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
JP6799586B2
(ja)
|
2015-08-28 |
2020-12-16 |
ザ ジェネラル ホスピタル コーポレイション |
遺伝子操作CRISPR−Cas9ヌクレアーゼ
|
IL241462A0
(en)
|
2015-09-10 |
2015-11-30 |
Yeda Res & Dev |
Heterologous engineering of betalain pigments in plants
|
KR20180043369A
(ko)
|
2015-09-11 |
2018-04-27 |
더 제너럴 하스피탈 코포레이션 |
뉴클레아제 dsb의 완전한 호출 및 시퀀싱(find-seq)
|
WO2017053879A1
(en)
|
2015-09-24 |
2017-03-30 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
WO2017058791A1
(en)
*
|
2015-09-29 |
2017-04-06 |
Agenovir Corporation |
Compositions and methods for treatment of latent viral infections
|
US9850484B2
(en)
|
2015-09-30 |
2017-12-26 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (Circle-seq)
|
WO2017059241A1
(en)
|
2015-10-02 |
2017-04-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP3365441A1
(en)
|
2015-10-22 |
2018-08-29 |
The Broad Institute Inc. |
Type vi-b crispr enzymes and systems
|
DK3350327T3
(en)
|
2015-10-23 |
2019-01-21 |
Caribou Biosciences Inc |
CONSTRUCTED CRISPR CLASS-2-NUCLEIC ACID TARGETING-NUCLEIC ACID
|
KR20180069898A
(ko)
|
2015-10-23 |
2018-06-25 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 편집제 및 그의 용도
|
WO2017074788A1
(en)
|
2015-10-27 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
WO2017075294A1
(en)
|
2015-10-28 |
2017-05-04 |
The Board Institute Inc. |
Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
US11092607B2
(en)
|
2015-10-28 |
2021-08-17 |
The Board Institute, Inc. |
Multiplex analysis of single cell constituents
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
EP3368689B1
(en)
|
2015-10-28 |
2020-06-17 |
The Broad Institute, Inc. |
Composition for modulating immune responses by use of immune cell gene signature
|
WO2017083852A1
(en)
|
2015-11-13 |
2017-05-18 |
MOORE, Tara |
Methods for the treatment of corneal dystrophies
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
US9839655B2
(en)
|
2015-11-20 |
2017-12-12 |
4D Pharma Research Limited |
Compositions comprising bacterial strains
|
GB201520497D0
(en)
|
2015-11-20 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
ES2930643T3
(es)
*
|
2015-11-23 |
2022-12-20 |
Univ California |
Seguimiento y manipulación de ARN celular a través de la administración nuclear de CRISPR/CAS9
|
WO2017095960A1
(en)
*
|
2015-11-30 |
2017-06-08 |
Synthetic Genomics, Inc. |
Compositions and methods for expressing genes in algae
|
WO2017095944A1
(en)
|
2015-11-30 |
2017-06-08 |
Flagship Pioneering, Inc. |
Methods and compositions relating to chondrisomes from blood products
|
WO2017093370A1
(en)
*
|
2015-12-03 |
2017-06-08 |
Technische Universität München |
T-cell specific genome editing
|
CN108473981B
(zh)
|
2015-12-04 |
2022-04-12 |
卡里布生物科学公司 |
工程化靶向核酸的核酸
|
US9988624B2
(en)
|
2015-12-07 |
2018-06-05 |
Zymergen Inc. |
Microbial strain improvement by a HTP genomic engineering platform
|
US11208649B2
(en)
|
2015-12-07 |
2021-12-28 |
Zymergen Inc. |
HTP genomic engineering platform
|
KR20180084756A
(ko)
|
2015-12-07 |
2018-07-25 |
지머젠 인코포레이티드 |
코리네박테리움 글루타미컴으로부터의 프로모터
|
US20190233814A1
(en)
|
2015-12-18 |
2019-08-01 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
WO2017114497A1
(en)
|
2015-12-30 |
2017-07-06 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
WO2017120504A1
(en)
|
2016-01-08 |
2017-07-13 |
Durfee Paul N |
Osteotropic nanoparticles for prevention or treatment of bone metastases
|
AU2017207281B2
(en)
|
2016-01-11 |
2022-03-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric proteins and methods of immunotherapy
|
CA3009194A1
(en)
|
2016-01-11 |
2017-07-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric proteins and methods of regulating gene expression
|
US10876129B2
(en)
|
2016-02-12 |
2020-12-29 |
Ceres, Inc. |
Methods and materials for high throughput testing of mutagenized allele combinations
|
EP3417061B1
(en)
|
2016-02-18 |
2022-10-26 |
The Regents of the University of California |
Methods and compositions for gene editing in stem cells
|
WO2017147196A1
(en)
|
2016-02-22 |
2017-08-31 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating immune phenotypes
|
CN105543196A
(zh)
*
|
2016-03-01 |
2016-05-04 |
中国水稻研究所 |
植物Cas9变体蛋白VRER及其编码基因与应用
|
CN105543195A
(zh)
*
|
2016-03-01 |
2016-05-04 |
中国水稻研究所 |
植物Cas9变体蛋白VQR及其编码基因与应用
|
JP6441536B2
(ja)
|
2016-03-04 |
2018-12-19 |
フォーディー ファーマ ピーエルシー4D Pharma Plc |
細菌株を含む組成物
|
GB201612191D0
(en)
|
2016-07-13 |
2016-08-24 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
CN109414414A
(zh)
|
2016-03-16 |
2019-03-01 |
戴维·格拉德斯通研究所 |
用于治疗肥胖症和/或糖尿病以及用于鉴定候选治疗剂的方法和组合物
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
WO2017161325A1
(en)
|
2016-03-17 |
2017-09-21 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating co-occurant cellular phenotypes
|
US20200291370A1
(en)
*
|
2016-03-18 |
2020-09-17 |
President And Fellows Of Harvard College |
Mutant Cas Proteins
|
WO2017165859A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Research Institute At Nationwide Children's Hospital |
Modified viral capsid proteins
|
US11512311B2
(en)
|
2016-03-25 |
2022-11-29 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
|
US11597924B2
(en)
|
2016-03-25 |
2023-03-07 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
EP4047092A1
(en)
|
2016-04-13 |
2022-08-24 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
SG11201809041TA
(en)
|
2016-04-15 |
2018-11-29 |
Novartis Ag |
Compositions and methods for selective protein expression
|
CA3026110A1
(en)
|
2016-04-19 |
2017-11-02 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
US20210155911A1
(en)
|
2016-04-19 |
2021-05-27 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
WO2017184786A1
(en)
|
2016-04-19 |
2017-10-26 |
The Broad Institute Inc. |
Cpf1 complexes with reduced indel activity
|
CN107304435A
(zh)
*
|
2016-04-22 |
2017-10-31 |
中国科学院青岛生物能源与过程研究所 |
一种Cas9/RNA系统及其应用
|
EP3449004B1
(en)
|
2016-04-29 |
2021-02-24 |
Poseida Therapeutics, Inc. |
Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
AU2017283713B2
(en)
|
2016-06-17 |
2021-04-08 |
Massachusetts Institute Of Technology |
Type VI CRISPR orthologs and systems
|
CN109688820B
(zh)
|
2016-06-24 |
2023-01-10 |
科罗拉多州立大学董事会(法人团体) |
用于生成条形码化组合文库的方法
|
MX2019000088A
(es)
|
2016-06-27 |
2019-08-29 |
Broad Inst Inc |
Composiciones y metodos para detectar y tratar la diabetes.
|
US10544411B2
(en)
|
2016-06-30 |
2020-01-28 |
Zymergen Inc. |
Methods for generating a glucose permease library and uses thereof
|
WO2018005655A2
(en)
|
2016-06-30 |
2018-01-04 |
Zymergen Inc. |
Methods for generating a bacterial hemoglobin library and uses thereof
|
TWI802545B
(zh)
|
2016-07-13 |
2023-05-21 |
英商4D製藥有限公司 |
包含細菌菌株之組合物
|
EP3484870B1
(en)
|
2016-07-13 |
2022-11-16 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
JP7219376B2
(ja)
|
2016-07-15 |
2023-02-08 |
ノバルティス アーゲー |
キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
|
WO2018026976A1
(en)
|
2016-08-02 |
2018-02-08 |
Editas Medicine, Inc. |
Compositions and methods for treating cep290 associated disease
|
GB2568182A
(en)
|
2016-08-03 |
2019-05-08 |
Harvard College |
Adenosine nucleobase editors and uses thereof
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
JP7215808B2
(ja)
*
|
2016-08-12 |
2023-01-31 |
ツールゲン インコーポレイテッド |
操作された免疫調節エレメントおよび変更された免疫
|
US11352647B2
(en)
|
2016-08-17 |
2022-06-07 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
WO2018035364A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute Inc. |
Product and methods useful for modulating and evaluating immune responses
|
WO2018035250A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Methods for identifying class 2 crispr-cas systems
|
US20200283743A1
(en)
|
2016-08-17 |
2020-09-10 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
EP4012032A1
(en)
*
|
2016-08-19 |
2022-06-15 |
Toolgen Incorporated |
Artificially engineered angiogenesis regulatory system
|
US20190185850A1
(en)
|
2016-08-20 |
2019-06-20 |
Avellino Lab Usa, Inc. |
Single guide rna/crispr/cas9 systems, and methods of use thereof
|
WO2020225754A1
(en)
|
2019-05-06 |
2020-11-12 |
Mcmullen Tara |
Crispr gene editing for autosomal dominant diseases
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
WO2018049025A2
(en)
|
2016-09-07 |
2018-03-15 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses
|
EP3510151B1
(en)
|
2016-09-09 |
2024-07-03 |
The Board of Trustees of the Leland Stanford Junior University |
High-throughput precision genome editing
|
IL247752A0
(en)
|
2016-09-11 |
2016-11-30 |
Yeda Res & Dev |
Compositions and methods for modulating gene expression for site-directed mutagenesis
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
CN109844126A
(zh)
|
2016-09-28 |
2019-06-04 |
诺华股份有限公司 |
基于多孔膜的大分子递送系统
|
CN110023494A
(zh)
|
2016-09-30 |
2019-07-16 |
加利福尼亚大学董事会 |
Rna指导的核酸修饰酶及其使用方法
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
GB201617559D0
(en)
|
2016-10-17 |
2016-11-30 |
University Court Of The University Of Edinburgh The |
Swine comprising modified cd163 and associated methods
|
WO2018075664A1
(en)
|
2016-10-18 |
2018-04-26 |
Regents Of The University Of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
JP7211940B2
(ja)
*
|
2016-10-28 |
2023-01-24 |
ジェネトン |
筋緊張性ジストロフィーの治療のための組成物および方法
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
CA3042259A1
(en)
|
2016-11-04 |
2018-05-11 |
Flagship Pioneering Innovations V. Inc. |
Novel plant cells, plants, and seeds
|
US9816093B1
(en)
|
2016-12-06 |
2017-11-14 |
Caribou Biosciences, Inc. |
Engineered nucleic acid-targeting nucleic acids
|
US11674128B2
(en)
*
|
2016-12-12 |
2023-06-13 |
Tsinghua University |
Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
|
GB201621123D0
(en)
|
2016-12-12 |
2017-01-25 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
WO2018112282A1
(en)
|
2016-12-14 |
2018-06-21 |
Ligandal, Inc. |
Compositions and methods for nucleic acid and/or protein payload delivery
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US11859219B1
(en)
|
2016-12-30 |
2024-01-02 |
Flagship Pioneering Innovations V, Inc. |
Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
ES2949801T3
(es)
|
2017-01-09 |
2023-10-03 |
Whitehead Inst Biomedical Res |
Métodos para alterar la expresión génica mediante la perturbación de multímeros de factores de transcripción que estructuran bucles reguladores
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
SG11201906795SA
(en)
|
2017-01-28 |
2019-08-27 |
Inari Agriculture Inc |
Novel plant cells, plants, and seeds
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
WO2018148511A1
(en)
|
2017-02-10 |
2018-08-16 |
Zymergen Inc. |
A modular universal plasmid design strategy for the assembly and editing of multiple dna constructs for multiple hosts
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
US11344629B2
(en)
|
2017-03-01 |
2022-05-31 |
Charles Jeffrey Brinker |
Active targeting of cells by monosized protocells
|
JP2020508685A
(ja)
|
2017-03-03 |
2020-03-26 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
サプレッサーtRNA及びデアミナーゼによる変異のRNAターゲティング
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
EP4361261A3
(en)
|
2017-03-15 |
2024-07-10 |
The Broad Institute Inc. |
Novel cas13b orthologues crispr enzymes and systems
|
WO2018170515A1
(en)
|
2017-03-17 |
2018-09-20 |
The Broad Institute, Inc. |
Methods for identifying and modulating co-occurant cellular phenotypes
|
GB2575930A
(en)
|
2017-03-23 |
2020-01-29 |
Harvard College |
Nucleobase editors comprising nucleic acid programmable DNA binding proteins
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
WO2018191553A1
(en)
|
2017-04-12 |
2018-10-18 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
CN110799645A
(zh)
|
2017-04-12 |
2020-02-14 |
博德研究所 |
新型vi型crispr直系同源物和系统
|
US20210115407A1
(en)
|
2017-04-12 |
2021-04-22 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
WO2018191750A2
(en)
|
2017-04-14 |
2018-10-18 |
The Broad Institute Inc. |
Novel delivery of large payloads
|
WO2018195019A1
(en)
|
2017-04-18 |
2018-10-25 |
The Broad Institute Inc. |
Compositions for detecting secretion and methods of use
|
US11591589B2
(en)
|
2017-04-21 |
2023-02-28 |
The General Hospital Corporation |
Variants of Cpf1 (Cas12a) with altered PAM specificity
|
US20200384115A1
(en)
|
2017-04-21 |
2020-12-10 |
The Broad Institute , Inc. |
Targeted delivery to beta cells
|
WO2018201086A1
(en)
|
2017-04-28 |
2018-11-01 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
WO2018209158A2
(en)
|
2017-05-10 |
2018-11-15 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
CN110869498A
(zh)
|
2017-05-10 |
2020-03-06 |
加利福尼亚大学董事会 |
经由核递送crispr/cas9导向编辑细胞rna
|
WO2019103857A1
(en)
|
2017-11-22 |
2019-05-31 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
WO2018213351A1
(en)
*
|
2017-05-16 |
2018-11-22 |
The Regents Of The University Of California |
Thermostable rna-guided endonucleases and methods of use thereof
|
JP7364472B2
(ja)
|
2017-05-18 |
2023-10-18 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
標的化された核酸編集のための系、方法、及び組成物
|
MA48941A
(fr)
|
2017-05-22 |
2020-04-08 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
MA41708A
(fr)
|
2017-05-24 |
2020-04-08 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
WO2018218166A1
(en)
|
2017-05-25 |
2018-11-29 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
US20200263186A1
(en)
|
2017-05-26 |
2020-08-20 |
North Carolina State University |
Altered guide rnas for modulating cas9 activity and methods of use
|
EP3409104A1
(en)
|
2017-05-31 |
2018-12-05 |
Vilmorin et Cie |
Tomato plant resistant to tomato yellow leaf curl virus, powdery mildew, and nematodes
|
WO2020249996A1
(en)
|
2019-06-14 |
2020-12-17 |
Vilmorin & Cie |
Resistance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus
|
EP3409106A1
(en)
|
2017-06-01 |
2018-12-05 |
Vilmorin et Cie |
Tolerance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus (tbrfv)
|
EP3635113A4
(en)
|
2017-06-05 |
2021-03-17 |
Fred Hutchinson Cancer Research Center |
GENOMIC SAFE HARBORS FOR GENETIC THERAPIES IN HUMAN STEM CELLS AND MANIPULATED NANOPARTICLES TO DELIVER TARGETED GENETIC THERAPIES
|
JP7227162B2
(ja)
|
2017-06-06 |
2023-02-21 |
ザイマージェン インコーポレイテッド |
真菌株を改良するためのhtpゲノム操作プラットフォーム
|
CN110945125A
(zh)
|
2017-06-06 |
2020-03-31 |
齐默尔根公司 |
用于改进大肠杆菌的htp基因工程改造平台
|
AU2018279112A1
(en)
*
|
2017-06-07 |
2019-12-19 |
Arc Bio, Llc |
Creation and use of guide nucleic acids
|
US10428319B2
(en)
|
2017-06-09 |
2019-10-01 |
Editas Medicine, Inc. |
Engineered Cas9 nucleases
|
US20200123203A1
(en)
|
2017-06-13 |
2020-04-23 |
Flagship Pioneering Innovations V, Inc. |
Compositions comprising curons and uses thereof
|
MA49010B1
(fr)
|
2017-06-14 |
2020-11-30 |
4D Pharma Res Ltd |
Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations
|
WO2018229188A1
(en)
|
2017-06-14 |
2018-12-20 |
4D Pharma Research Limited |
Compositions comprising bacterial strains
|
EP3638218A4
(en)
|
2017-06-14 |
2021-06-09 |
The Broad Institute, Inc. |
COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
|
CA3065326A1
(en)
|
2017-06-14 |
2018-12-20 |
Wisconsin Alumni Research Foundation |
Modified guide rnas, crispr-ribonucleotprotein complexes and methods of use
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
WO2019005884A1
(en)
|
2017-06-26 |
2019-01-03 |
The Broad Institute, Inc. |
CRISPR / CAS-ADENINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED NUCLEIC ACID EDITION
|
WO2019003193A1
(en)
|
2017-06-30 |
2019-01-03 |
Novartis Ag |
METHODS FOR TREATING DISEASES USING GENE EDITING SYSTEMS
|
CN111511375A
(zh)
|
2017-06-30 |
2020-08-07 |
因提玛生物科学公司 |
用于基因治疗的腺相关病毒载体
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
WO2019018551A2
(en)
|
2017-07-18 |
2019-01-24 |
Lee Tzumin |
METHODS AND COMPOSITIONS FOR GENETICALLY GENETIC HANDLING OF GENES AND CELLS
|
WO2019023291A2
(en)
|
2017-07-25 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR PRODUCTION AND DECODING OF GUIDE RNA LIBRARIES AND USES THEREOF
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
KR20200036912A
(ko)
|
2017-07-31 |
2020-04-07 |
리플렉션 바이오테크놀러지스 리미티드 |
안과 질환을 위한 세포 모델 및 치료요법
|
AU2018320865B2
(en)
|
2017-08-23 |
2023-09-14 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases with altered PAM specificity
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
WO2019051419A1
(en)
*
|
2017-09-08 |
2019-03-14 |
University Of North Texas Health Science Center |
MODIFIED CASE VARIANTS9
|
KR20200090151A
(ko)
|
2017-09-20 |
2020-07-28 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
신규한 항-hla-a2 항체 및 이의 용도
|
IT201700105372A1
(it)
*
|
2017-09-20 |
2019-03-20 |
Fondazione St Italiano Tecnologia |
Molecola di acido nucleico funzionale e relativo uso
|
KR102338449B1
(ko)
|
2017-09-21 |
2021-12-10 |
더 브로드 인스티튜트, 인코퍼레이티드 |
표적화된 핵산 편집을 위한 시스템, 방법, 및 조성물
|
WO2019060759A1
(en)
|
2017-09-21 |
2019-03-28 |
Dana-Farber Cancer Institute, Inc. |
ISOLATION, PRESERVATION, COMPOSITIONS AND USES OF PLANT EXTRACTS JUSTICIA
|
US10933027B1
(en)
|
2017-09-25 |
2021-03-02 |
National Technology & Engineering Solutions Of Sandia, Llc |
Expanded pore particles and delivery methods thereof
|
EP3692152A4
(en)
|
2017-10-04 |
2021-12-01 |
The Broad Institute, Inc. |
PROCESSES AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF CHROMATIN LOOPS AND / OR DOMAINS
|
EP3694993A4
(en)
|
2017-10-11 |
2021-10-13 |
The General Hospital Corporation |
METHOD OF DETECTING A SITE-SPECIFIC AND UNDESIRED GENOMIC DESAMINATION INDUCED BY BASE EDITING TECHNOLOGIES
|
WO2019079362A1
(en)
|
2017-10-16 |
2019-04-25 |
Massachusetts Institute Of Technology |
HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
|
CN111757937A
(zh)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
腺苷碱基编辑器的用途
|
SG11202003024WA
(en)
|
2017-10-20 |
2020-05-28 |
Hutchinson Fred Cancer Res |
Systems and methods to produce b cells genetically modified to express selected antibodies
|
WO2019089803A1
(en)
|
2017-10-31 |
2019-05-09 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
EP3704245A1
(en)
|
2017-11-01 |
2020-09-09 |
Novartis AG |
Synthetic rnas and methods of use
|
US12018080B2
(en)
|
2017-11-13 |
2024-06-25 |
The Broad Institute, Inc. |
Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway
|
CN111448313A
(zh)
|
2017-11-16 |
2020-07-24 |
阿斯利康(瑞典)有限公司 |
用于改善基于Cas9的敲入策略的有效性的组合物和方法
|
KR20200100060A
(ko)
|
2017-11-17 |
2020-08-25 |
이오반스 바이오테라퓨틱스, 인크. |
미세 바늘 흡인물 및 소형 생검물로부터의 til 확장
|
US11332736B2
(en)
|
2017-12-07 |
2022-05-17 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
CN109912702B
(zh)
*
|
2017-12-13 |
2021-03-16 |
中国科学院遗传与发育生物学研究所 |
蛋白质OsARE1在调控植物抗低氮性中的应用
|
MA51138A
(fr)
|
2017-12-14 |
2020-10-21 |
Bayer Healthcare Llc |
Nouveaux systèmes d'endonucléases arn-programmables et leurs utilisations dans l'édition de génome et d'autres applications
|
US20190201548A1
(en)
|
2017-12-29 |
2019-07-04 |
Rubius Therapeutics, Inc. |
Gene editing and targeted transcriptional modulation for engineering erythroid cells
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
MX2020007466A
(es)
|
2018-01-12 |
2020-11-12 |
Basf Se |
Gen subyacente al qtl de la cantidad de espiguillas por espiga en trigo en el cromosoma 7a.
|
JP7483612B2
(ja)
|
2018-01-17 |
2024-05-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ゲノム編集効率を増加するためのキノキサリノン化合物、組成物、方法、およびキット
|
EA202091709A1
(ru)
|
2018-01-17 |
2020-11-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Ингибиторы днк-пк
|
EP3740480B1
(en)
|
2018-01-17 |
2024-03-06 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
US11926835B1
(en)
|
2018-01-29 |
2024-03-12 |
Inari Agriculture Technology, Inc. |
Methods for efficient tomato genome editing
|
KR20200119239A
(ko)
|
2018-02-08 |
2020-10-19 |
지머젠 인코포레이티드 |
코리네박테리움에서 crispr을 사용하는 게놈 편집
|
SG11202008956XA
(en)
|
2018-03-14 |
2020-10-29 |
Editas Medicine Inc |
Systems and methods for the treatment of hemoglobinopathies
|
AU2019239957A1
(en)
|
2018-03-19 |
2020-09-10 |
Bayer Healthcare Llc |
Novel RNA-programmable endonuclease systems and uses thereof
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
US11981739B2
(en)
|
2018-04-13 |
2024-05-14 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
JP7460539B2
(ja)
|
2018-04-17 |
2024-04-02 |
ザ ジェネラル ホスピタル コーポレイション |
核酸を結合、修飾、および切断する物質の基質選択性および部位のためのin vitroでの高感度アッセイ
|
WO2019204585A1
(en)
|
2018-04-19 |
2019-10-24 |
Massachusetts Institute Of Technology |
Single-stranded break detection in double-stranded dna
|
CA3096713A1
(en)
|
2018-04-19 |
2019-10-24 |
The Regents Of The University Of California |
Compositions and methods for gene editing
|
SI3560330T1
(sl)
|
2018-04-24 |
2022-08-31 |
KWS SAAT SE & Co. KGaA |
Rastline z izboljšano prebavljivostjo in markerskimi haplotipi
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
CN112334510A
(zh)
|
2018-04-27 |
2021-02-05 |
基因编辑有限公司 |
阳离子聚合物和用于生物分子递送的用途
|
MA52533A
(fr)
|
2018-04-27 |
2021-03-03 |
Iovance Biotherapeutics Inc |
Procédé en circuit fermé pour l'amplification et l'edition de gènes de lymphocytes d'infiltration des tumeurs et leurs utilisations en immunothérapie
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019210268A2
(en)
|
2018-04-27 |
2019-10-31 |
The Broad Institute, Inc. |
Sequencing-based proteomics
|
WO2019213660A2
(en)
|
2018-05-04 |
2019-11-07 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
|
BR112020022612A2
(pt)
|
2018-05-10 |
2021-02-09 |
Auxolytic Ltd |
métodos e composições de terapia genética usando células reguláveis auxotróficas
|
GB2589246A
(en)
|
2018-05-16 |
2021-05-26 |
Synthego Corp |
Methods and systems for guide RNA design and use
|
WO2019232542A2
(en)
|
2018-06-01 |
2019-12-05 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
US11866719B1
(en)
|
2018-06-04 |
2024-01-09 |
Inari Agriculture Technology, Inc. |
Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
US10227576B1
(en)
|
2018-06-13 |
2019-03-12 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Bcmaキメラ抗原受容体及びその使用
|
US11045554B1
(en)
|
2018-06-22 |
2021-06-29 |
National Technology & Engineering Solutions Of Sandia, Llc |
Lipid-coated particles for treating viral infections
|
EP3814527B1
(en)
|
2018-06-26 |
2023-02-22 |
Massachusetts Institute of Technology |
Crispr effector system based amplification methods, systems, and diagnostics
|
JP2021528975A
(ja)
|
2018-06-26 |
2021-10-28 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
Crispr/cas及びトランスポザーゼを利用した増幅用の組成物、システム、及び方法
|
WO2020002579A1
(en)
|
2018-06-29 |
2020-01-02 |
Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis |
Tweak-receptor agonists for use in combination with immunotherapy of a cancer
|
JP2021530212A
(ja)
|
2018-07-13 |
2021-11-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
レトロトランスポゾンベースの送達媒体及びその使用方法
|
CA3111432A1
(en)
|
2018-07-31 |
2020-02-06 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
WO2020033601A1
(en)
|
2018-08-07 |
2020-02-13 |
The Broad Institute, Inc. |
Novel cas12b enzymes and systems
|
EP3607819A1
(en)
|
2018-08-10 |
2020-02-12 |
Vilmorin et Cie |
Resistance to xanthomonas campestris pv. campestris (xcc) in cauliflower
|
SG11202101415UA
(en)
|
2018-08-10 |
2021-03-30 |
Sangamo Therapeutics France |
New car constructs comprising tnfr2 domains
|
JP2021533773A
(ja)
|
2018-08-15 |
2021-12-09 |
ザイマージェン インコーポレイテッド |
ハイスループット代謝操作におけるCRISPRiの適用
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
WO2020041387A1
(en)
|
2018-08-20 |
2020-02-27 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
WO2020041249A1
(en)
|
2018-08-23 |
2020-02-27 |
Sangamo Therapeutics, Inc. |
Engineered target specific base editors
|
KR20210049859A
(ko)
|
2018-08-28 |
2021-05-06 |
플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 |
게놈을 조절하는 방법 및 조성물
|
US11459551B1
(en)
|
2018-08-31 |
2022-10-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
EP3847650A1
(en)
|
2018-09-06 |
2021-07-14 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
WO2020049158A1
(en)
|
2018-09-07 |
2020-03-12 |
Astrazeneca Ab |
Compositions and methods for improved nucleases
|
EP4268831A3
(en)
|
2018-09-12 |
2024-05-22 |
Fred Hutchinson Cancer Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
CA3113095A1
(en)
|
2018-09-18 |
2020-03-26 |
Vnv Newco Inc. |
Arc-based capsids and uses thereof
|
JP2022501374A
(ja)
|
2018-09-21 |
2022-01-06 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
糖尿病を治療するための方法及び組成物、ならびに分泌タンパク質をコードするmRNAを濃縮する方法
|
WO2020067004A1
(ja)
*
|
2018-09-25 |
2020-04-02 |
公益財団法人微生物化学研究会 |
新規ウイルスベクターおよびその製造方法と使用方法
|
WO2020077236A1
(en)
|
2018-10-12 |
2020-04-16 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
US20210395709A1
(en)
*
|
2018-10-18 |
2021-12-23 |
Chan Zuckerberg Biohub, Inc. |
Methods and compositions involving thermostable cas9 protein variants
|
WO2020086910A1
(en)
|
2018-10-24 |
2020-04-30 |
Genedit Inc. |
Cationic polymer with alkyl side chains and use for biomolecule delivery
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
CN113166741A
(zh)
|
2018-10-31 |
2021-07-23 |
齐默尔根公司 |
Dna文库的多重确定性组装
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
AU2019375416A1
(en)
|
2018-11-05 |
2021-05-27 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive T-cells
|
US20220033775A1
(en)
|
2018-11-05 |
2022-02-03 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathways inhibitors
|
US20220090018A1
(en)
|
2018-11-05 |
2022-03-24 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and used of the same in immunotherapy
|
US11739320B2
(en)
|
2018-11-05 |
2023-08-29 |
Wisconsin Alumni Research Foundation |
Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
|
JP2022512899A
(ja)
|
2018-11-05 |
2022-02-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
抗pd-1抗体に対して不応性のnsclc患者の治療
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
US10934536B2
(en)
|
2018-12-14 |
2021-03-02 |
Pioneer Hi-Bred International, Inc. |
CRISPR-CAS systems for genome editing
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
CN113544266A
(zh)
|
2018-12-17 |
2021-10-22 |
博德研究所 |
Crispr相关转座酶系统和其使用方法
|
CA3123392A1
(en)
|
2018-12-19 |
2020-06-25 |
Iovance Biotherapeutics, Inc. |
Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
|
JP2022515124A
(ja)
|
2018-12-19 |
2022-02-17 |
キングス カレッジ ロンドン |
免疫療法および組成物
|
BR112021012665A2
(pt)
*
|
2018-12-27 |
2021-11-03 |
Lifeedit Therapeutics Inc |
Polipeptídeos úteis para edição de genes e métodos de uso
|
AU2020205150A1
(en)
|
2019-01-03 |
2021-07-22 |
Assistance Publique-Hôpitaux De Paris (Aphp) |
Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
WO2020163856A1
(en)
|
2019-02-10 |
2020-08-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Modified mitochondrion and methods of use thereof
|
MX2021009886A
(es)
*
|
2019-02-14 |
2021-10-13 |
Metagenomi Inc |
Enzimas con dominios ruvc.
|
WO2020168234A1
(en)
*
|
2019-02-14 |
2020-08-20 |
Metagenomi Ip Technologies, Llc |
Enzymes with ruvc domains
|
US10982200B2
(en)
|
2019-02-14 |
2021-04-20 |
Metagenomi Ip Technologies, Llc |
Enzymes with RuvC domains
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
AU2020233284A1
(en)
|
2019-03-01 |
2021-09-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2020181101A1
(en)
|
2019-03-07 |
2020-09-10 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
JP2022524043A
(ja)
|
2019-03-08 |
2022-04-27 |
ザイマージェン インコーポレイテッド |
微生物の反復ゲノム編集
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
CA3132840A1
(en)
|
2019-03-08 |
2020-09-17 |
Obsidian Therapeutics, Inc. |
Human carbonic anhydrase 2 compositions and methods for tunable regulation
|
CN113891936A
(zh)
|
2019-03-19 |
2022-01-04 |
布罗德研究所股份有限公司 |
编辑核苷酸序列的方法和组合物
|
US20220162649A1
(en)
|
2019-04-01 |
2022-05-26 |
The Broad Institute, Inc. |
Novel nucleic acid modifiers
|
GB201905360D0
(en)
|
2019-04-16 |
2019-05-29 |
Univ Nottingham |
Fungal strains, production and uses thereof
|
WO2020219776A1
(en)
|
2019-04-23 |
2020-10-29 |
Genedit Inc. |
Cationic polymer with alkyl side chains
|
WO2020219742A1
(en)
|
2019-04-24 |
2020-10-29 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
SG11202112161TA
(en)
|
2019-05-03 |
2021-12-30 |
Specific Biologics Inc |
Lipid-encapsulated dual-cleaving endonuclease for dna and gene editing
|
EP3969607A1
(en)
|
2019-05-13 |
2022-03-23 |
KWS SAAT SE & Co. KGaA |
Drought tolerance in corn
|
WO2020232029A1
(en)
|
2019-05-13 |
2020-11-19 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
US20220220469A1
(en)
|
2019-05-20 |
2022-07-14 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
WO2020236967A1
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Random crispr-cas deletion mutant
|
AR118995A1
(es)
|
2019-05-25 |
2021-11-17 |
Kws Saat Se & Co Kgaa |
Mejorador de la inducción de haploides
|
KR20220013570A
(ko)
|
2019-05-28 |
2022-02-04 |
진에딧 인코포레이티드 |
생체분자 전달을 위한 다중 관능화된 곁사슬을 포함하는 폴리머
|
WO2020243661A1
(en)
|
2019-05-31 |
2020-12-03 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
WO2020244759A1
(en)
|
2019-06-05 |
2020-12-10 |
Klemm & Sohn Gmbh & Co. Kg |
New plants having a white foliage phenotype
|
WO2020254850A1
(en)
|
2019-06-21 |
2020-12-24 |
Vilmorin & Cie |
Improvement of quality and permanence of green color of peppers at maturity and over-maturity
|
WO2020264016A1
(en)
|
2019-06-25 |
2020-12-30 |
Inari Agriculture, Inc. |
Improved homology dependent repair genome editing
|
EP3994270A1
(en)
|
2019-07-02 |
2022-05-11 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
WO2021009299A1
(en)
|
2019-07-17 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bcl-xl:fkbp12 fusion proteins suitable for screening agents capable of slowing down the aging process
|
WO2021019272A1
(en)
|
2019-07-31 |
2021-02-04 |
Vilmorin & Cie |
Tolerance to tolcndv in cucumber
|
AU2020324386A1
(en)
*
|
2019-08-02 |
2022-02-24 |
Monsanto Technology Llc |
Methods and compositions to promote targeted genome modifications using HUH endonucleases
|
EP3772542A1
(en)
|
2019-08-07 |
2021-02-10 |
KWS SAAT SE & Co. KGaA |
Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
|
JP2022543451A
(ja)
*
|
2019-08-08 |
2022-10-12 |
▲復▼旦大学 |
CRISPR/Cas9遺伝子編集システムおよびその適用
|
WO2021028359A1
(en)
|
2019-08-09 |
2021-02-18 |
Sangamo Therapeutics France |
Controlled expression of chimeric antigen receptors in t cells
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
EP4028514A1
(en)
*
|
2019-09-09 |
2022-07-20 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
AU2020348879A1
(en)
|
2019-09-20 |
2022-04-14 |
Massachusetts Institute Of Technology |
Novel type VI CRISPR enzymes and systems
|
EP4048807A1
(en)
|
2019-09-23 |
2022-08-31 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
CN114846022A
(zh)
|
2019-10-17 |
2022-08-02 |
科沃施种子欧洲股份两合公司 |
通过阻抑基因的下调增强作物的疾病抗性
|
WO2021081378A1
(en)
|
2019-10-25 |
2021-04-29 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
KR20220097984A
(ko)
*
|
2019-11-13 |
2022-07-08 |
크리스퍼 테라퓨틱스 아게 |
키메라 항원 수용체를 발현하는 t 세포를 제조하기 위한 제조 방법
|
CA3158118A1
(en)
*
|
2019-11-13 |
2021-05-20 |
Julie Carson |
Methods of manufacturing car-t cells
|
EP4057802A1
(en)
|
2019-11-14 |
2022-09-21 |
Vilmorin & Cie |
Resistance to acidovorax valerianellae in corn salad
|
KR20220104766A
(ko)
|
2019-11-22 |
2022-07-26 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
약물 전달을 위한 이온성 액체
|
CA3159944A1
(en)
|
2019-12-02 |
2021-06-10 |
David HUSS |
Therapeutic editing
|
CA3161104A1
(en)
|
2019-12-11 |
2021-06-17 |
Cecile Chartier-Courtaud |
Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
|
IL271656A
(en)
|
2019-12-22 |
2021-06-30 |
Yeda Res & Dev |
System and methods for identifying cells that have undergone genome editing
|
EP4090743A1
(en)
|
2020-01-13 |
2022-11-23 |
Sana Biotechnology, Inc. |
Modification of blood type antigens
|
IL294715A
(en)
|
2020-01-23 |
2022-09-01 |
Childrens Medical Ct Corp |
Inducible t-cell differentiation from human pluripotent stem cells
|
EP3872190A1
(en)
|
2020-02-26 |
2021-09-01 |
Antibodies-Online GmbH |
A method of using cut&run or cut&tag to validate crispr-cas targeting
|
CN116096886A
(zh)
|
2020-03-11 |
2023-05-09 |
欧米茄治疗公司 |
用于调节叉头框p3(foxp3)基因表达的组合物和方法
|
CA3172120A1
(en)
|
2020-03-20 |
2021-09-23 |
Inserm (Institut De La Sante Et De La Recherche Medicale) |
Chimeric antigen receptor specific for human cd45rc and uses thereof
|
KR20220161383A
(ko)
|
2020-03-31 |
2022-12-06 |
메타지노미, 인크. |
클래스 ii, 유형 ii crispr 시스템
|
US11433121B1
(en)
|
2020-04-03 |
2022-09-06 |
National Technology & Engineering Solutions Of Sandia, Llc |
Lipid composition for the delivery of therapeutic cargos
|
US20210319851A1
(en)
|
2020-04-03 |
2021-10-14 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
WO2021216622A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
|
WO2021216623A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
|
WO2021217082A1
(en)
|
2020-04-23 |
2021-10-28 |
Genedit Inc. |
Polymer with cationic and hydrophobic side chains
|
US20230151343A1
(en)
*
|
2020-04-24 |
2023-05-18 |
Institute For Basic Science |
Genome editing using cas9 or cas9 variant
|
JP2023523855A
(ja)
|
2020-05-04 |
2023-06-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用
|
EP4146797A1
(en)
|
2020-05-06 |
2023-03-15 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
CA3177481A1
(en)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
PE20230080A1
(es)
|
2020-05-29 |
2023-01-11 |
Kws Saat Se And Co Kgaa |
Induccion de haploides en plantas
|
WO2021245435A1
(en)
|
2020-06-03 |
2021-12-09 |
Vilmorin & Cie |
Melon plants resistant to scab disease, aphids and powdery mildew
|
MA59015B1
(fr)
|
2020-06-05 |
2023-11-30 |
Vilmorin & Cie |
Résistance des plants de tomate - solanum lycopersicum - au tobrfv
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
EP4189071A1
(en)
|
2020-08-03 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
WO2022034474A1
(en)
|
2020-08-10 |
2022-02-17 |
Novartis Ag |
Treatments for retinal degenerative diseases
|
CA3188867A1
(en)
|
2020-08-20 |
2022-02-24 |
Xueyin Wang |
Compositions and methods for treating ceacam positive cancers
|
WO2022040454A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
CA3189510A1
(en)
|
2020-08-20 |
2022-02-24 |
Julyun OH |
Compositions and methods for treating egfr positive cancers
|
MA60153A1
(fr)
|
2020-10-02 |
2023-08-31 |
Vilmorin & Cie |
Melon à durée de conservation prolongée
|
EP4225330A1
(en)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022101286A1
(en)
|
2020-11-11 |
2022-05-19 |
Leibniz-Institut Für Pflanzenbiochemie |
Fusion protein for editing endogenous dna of a eukaryotic cell
|
WO2022104061A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
EP4001429A1
(en)
|
2020-11-16 |
2022-05-25 |
Antibodies-Online GmbH |
Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq)
|
WO2022117884A1
(en)
|
2020-12-03 |
2022-06-09 |
Vilmorin & Cie |
Tomato plants resistant to tobrfv, tmv, tomv and tommv and corresponding resistance genes
|
WO2022133140A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
EP4262827A1
(en)
|
2020-12-17 |
2023-10-25 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
JP2024501287A
(ja)
|
2020-12-23 |
2024-01-11 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
RNAを閉じ込めたアネロウイルス(Anellovirus)キャプシドのインビトロアセンブリ
|
EP4284919A1
(en)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
KR20230147109A
(ko)
|
2021-02-16 |
2023-10-20 |
에이투 바이오쎄라퓨틱스, 인크. |
Her2 양성 암을 치료하기 위한 조성물 및 방법
|
GB202103131D0
(en)
|
2021-03-05 |
2021-04-21 |
Biosystems Tech Limited |
Method for preparation of research organisms
|
EP4308691A1
(en)
|
2021-03-19 |
2024-01-24 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
KR20240009393A
(ko)
|
2021-03-31 |
2024-01-22 |
엔트라다 테라퓨틱스, 인크. |
사이클릭 세포 침투 펩티드
|
WO2022208489A1
(en)
|
2021-04-02 |
2022-10-06 |
Vilmorin & Cie |
Semi-determinate or determinate growth habit trait in cucurbita
|
EP4326287A2
(en)
|
2021-04-19 |
2024-02-28 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
JP2024517607A
(ja)
*
|
2021-04-30 |
2024-04-23 |
メタゲノミ,インク. |
Ruvcドメインを有する酵素
|
CA3217862A1
(en)
|
2021-05-05 |
2022-11-10 |
Radius Pharmaceuticals, Inc. |
Animal model having homologous recombination of mouse pth1 receptor
|
EP4337261A2
(en)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating mrna splicing
|
CA3218805A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for intracellular therapeutics
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
EP4340850A1
(en)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
JP2024520528A
(ja)
|
2021-06-01 |
2024-05-24 |
アーバー バイオテクノロジーズ, インコーポレイテッド |
Crisprヌクレアーゼを含む遺伝子編集システム及びそれらの使用
|
WO2022261561A1
(en)
|
2021-06-11 |
2022-12-15 |
Genedit Inc. |
Biodegradable polymer comprising side chains with polyamine and polyalkylene oxide groups
|
JP2024524291A
(ja)
|
2021-06-23 |
2024-07-05 |
エントラーダ セラピューティクス,インコーポレイティド |
Cugリピートを標的とするためのアンチセンス化合物及び方法
|
WO2023279118A2
(en)
*
|
2021-07-02 |
2023-01-05 |
University Of Maryland, College Park |
Cytidine deaminases and methods of genome editing using the same
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
EP4373270A2
(en)
|
2021-07-22 |
2024-05-29 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
EP4376596A1
(en)
|
2021-07-30 |
2024-06-05 |
KWS SAAT SE & Co. KGaA |
Plants with improved digestibility and marker haplotypes
|
WO2023012325A1
(en)
|
2021-08-06 |
2023-02-09 |
Vilmorin & Cie |
Resistance to leveillula taurica in pepper
|
EP4396357A1
(en)
|
2021-09-02 |
2024-07-10 |
SESVanderHave NV |
Methods and compositions for ppo herbicide tolerance
|
JP7125727B1
(ja)
|
2021-09-07 |
2022-08-25 |
国立大学法人千葉大学 |
核酸配列改変用組成物および核酸配列の標的部位を改変する方法
|
WO2023039424A2
(en)
*
|
2021-09-08 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating a genome
|
KR20240055811A
(ko)
|
2021-09-10 |
2024-04-29 |
애질런트 테크놀로지스, 인크. |
프라임 편집을 위한 화학적 변형을 갖는 가이드 rna
|
IL311538A
(en)
|
2021-09-20 |
2024-05-01 |
Revivicor Inc |
Transgenic multigene pigs comprising ten genetic alterations for xenotransplantation
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
WO2023060132A1
(en)
*
|
2021-10-05 |
2023-04-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Allele specific editing to treat fus-induced neurodegeneration
|
CA3233824A1
(en)
|
2021-10-08 |
2023-04-13 |
Samir Mitragotri |
Ionic liquids for drug delivery
|
TW202331735A
(zh)
|
2021-10-27 |
2023-08-01 |
美商艾歐凡斯生物治療公司 |
協調用於患者特異性免疫療法之細胞之製造的系統及方法
|
IL312452A
(en)
|
2021-11-01 |
2024-06-01 |
Tome Biosciences Inc |
A transformant has a single structure for the simultaneous transfer of a gene editing mechanism and a nucleic acid cargo
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023085433A1
(ja)
|
2021-11-15 |
2023-05-19 |
国立大学法人鳥取大学 |
ヒト細胞内でヒト人工染色体ベクターを作製する方法
|
WO2023093862A1
(en)
|
2021-11-26 |
2023-06-01 |
Epigenic Therapeutics Inc. |
Method of modulating pcsk9 and uses thereof
|
GB202118058D0
(en)
|
2021-12-14 |
2022-01-26 |
Univ Warwick |
Methods to increase yields in crops
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
TW202342757A
(zh)
|
2021-12-17 |
2023-11-01 |
美商薩那生物科技公司 |
經修飾副黏液病毒科附著醣蛋白
|
WO2023115039A2
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
AU2022420615A1
(en)
|
2021-12-22 |
2024-07-04 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
AU2022417615A1
(en)
|
2021-12-23 |
2024-06-27 |
University Of Massachusetts |
Therapeutic treatment for fragile x-associated disorder
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023150518A1
(en)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023156587A1
(en)
|
2022-02-18 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
EP4256950A1
(en)
|
2022-04-06 |
2023-10-11 |
Vilmorin et Cie |
Tolerance to cgmmv in cucumber
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
WO2023220035A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
WO2023219933A1
(en)
|
2022-05-09 |
2023-11-16 |
Entrada Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acid therapeutics
|
WO2023220043A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023230578A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating circulating factors
|
WO2023230570A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating genetic drivers
|
WO2023230549A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulation of tumor suppressors and oncogenes
|
WO2023230566A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulating cytokines
|
WO2023230573A2
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for modulation of immune responses
|
WO2024005864A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
EP4299733A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
EP4299739A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
GB2621813A
(en)
|
2022-06-30 |
2024-02-28 |
Univ Newcastle |
Preventing disease recurrence in Mitochondrial replacement therapy
|
WO2024005863A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
WO2024023734A1
(en)
|
2022-07-26 |
2024-02-01 |
Bit Bio Limited |
MULTI-gRNA GENOME EDITING
|
WO2024030930A2
(en)
*
|
2022-08-01 |
2024-02-08 |
The Johns Hopkins University |
Compositions and methods for modifying muller glial cells
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024042199A1
(en)
|
2022-08-26 |
2024-02-29 |
KWS SAAT SE & Co. KGaA |
Use of paired genes in hybrid breeding
|
WO2024047587A1
(en)
|
2022-08-31 |
2024-03-07 |
Regel Therapeutics, Inc. |
Cas-phi compositions and methods of use
|
WO2024050544A2
(en)
|
2022-09-01 |
2024-03-07 |
J.R. Simplot Company |
Enhanced targeted knock-in frequency in host genomes through crispr exonuclease processing
|
WO2024047605A1
(en)
|
2022-09-01 |
2024-03-07 |
SESVanderHave NV |
Methods and compositions for ppo herbicide tolerance
|
WO2024052318A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
WO2024074888A2
(en)
|
2022-10-03 |
2024-04-11 |
The Regents Of The University Of California |
Circumventing barriers to hybrid crops from genetically distant crosses
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
WO2024141599A1
(en)
|
2022-12-29 |
2024-07-04 |
Vilmorin & Cie |
Tomato plants resistant to resistance-breaking tswv strains and corresponding resistance genes
|